Trial · NCT01476787
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review | Rituximab-Lenalidomide | 48.1 | 95% Confidence Interval 43.7 to 52.6 | Percent of participants | |
| Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review | Investigator Choice | 53.0 | 95% Confidence Interval 48.6 to 57.4 | Percent of participants | |
| Progression-free Survival (PFS) | Rituximab-Lenalidomide | 120.2 | 95% Confidence Interval 104.9 to 126.3 | Months | |
| Progression-free Survival (PFS) | Investigator Choice | 123.8 | 95% Confidence Interval 107.4 to NA | Months | |
| Complete Response Rate (CR) at 120 Weeks Per Independent Central Review | Rituximab-Lenalidomide | 27.7 | 95% Confidence Interval 23.8 to 31.8 | Percent of participants | |
| Complete Response Rate (CR) at 120 Weeks Per Independent Central Review | Investigator Choice | 32.7 | 95% Confidence Interval 28.7 to 36.9 | Percent of participants | |
| Event-free Survival (EFS) | Rituximab-Lenalidomide | 130.6 | 95% Confidence Interval 121.9 to NA | Months | |
| Event-free Survival (EFS) | Investigator Choice | 132.3 | 95% Confidence Interval 115.7 to NA | Months | |
| Overall Survival (OS) | Rituximab-Lenalidomide | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival (OS) | Investigator Choice | NA | 95% Confidence Interval NA to NA | Months | |
| Time to Next Anti-Lymphoma Treatment (TTNLT) | Rituximab-Lenalidomide | NA | 95% Confidence Interval NA to NA | Months | |
| Time to Next Anti-Lymphoma Treatment (TTNLT) | Investigator Choice | NA | 95% Confidence Interval NA to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01476787/results